Table 1.
Baseline characteristics of the study population
| Parameter | All patients (n = 146) | Patients without endpoint (n = 112) | Patients with endpoint (n = 34) | P-value |
|---|---|---|---|---|
| Clinical data | ||||
| Age (years) | 53 ± 14 | 52 ± 14 | 57 ± 15 | NS |
| Male gender, n (%) | 116 (80) | 90 (80) | 26 (76) | NS |
| Arterial hypertension, n (%) | 64 (44) | 48 (43) | 16 (47) | NS |
| Hyperlipidaemia, n (%) | 27 (18) | 21 (19) | 6 (18) | NS |
| Smoking, n (%) | 50 (34) | 41 (37) | 9 (36) | NS |
| Diabetes mellitus, n (%) | 20 (14) | 16 (14) | 4 (12) | NS |
| Familiar cardiomyopathy, n (%) | 14 (10) | 13 (12) | 1 (3) | NS |
| Body mass index (kg/m2) | 25.7 ± 3.9 | 25.7 ± 3.9 | 25.5 ± 3.7 | NS |
| NYHA Class | ||||
| I, n (%) | 18 (12) | 13 (12) | 5 (15) | NS |
| II, n (%) | 72 (49) | 60 (54) | 12 (35) | NS |
| III, n (%) | 56 (38) | 39 (35) | 17 (50) | NS |
| Laboratory data | ||||
| Serum creatinine (mg/dL) | 1.12 ± 1.00 | 1.13 ± 1.13 | 1.07 ± 0.35 | NS |
| Cardiac medications | ||||
| β-blockers, n (%) | 141 (97) | 108 (96) | 33 (97) | NS |
| ACE-Inhibitors/AT II blockers, n (%) | 143 (98) | 109 (97) | 34 (100) | NS |
| Spironolactone, n (%) | 79 (54) | 61 (54) | 18 (53) | NS |
| Diuretics, n (%) | 91 (62) | 67 (60) | 24 (71) | NS |
| Digoxin, n (%) | 31 (21) | 18 (16) | 13 (38) | <0.05 |
| Coumadine, n (%) | 61 (42) | 44 (39) | 17 (50) | NS |